Compendium of Cancer Genome Aberrations

CNS5:Volunteer Assignments and Opportunities: Difference between revisions

[checked revision][checked revision]
← Older edit
VisualWikitext
No edit summary
Editor updated for a page on volunteer assignments
 
(25 intermediate revisions by 3 users not shown)
Line 6: Line 6:


To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br />
To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br />
__TOC__
{| class="wikitable" style="margin:auto"
{| class="wikitable" style="margin:auto"
|+<big>WHO Classification of Tumours of the Central Nervous System (5th Edition) Content</big>
|+<big>WHO Classification of Tumours of the Central Nervous System (5th Edition) Content</big>
Line 17: Line 18:
!'''Notes'''
!'''Notes'''
|-
|-
|CHAPTER 2 (GLIOMAS, GLIONEURONAL TUMOURS, AND NEURONAL TUMOURS)
|
====CHAPTER 2 (GLIOMAS, GLIONEURONAL TUMOURS, AND NEURONAL TUMOURS)====
|
|
----
----
Line 42: Line 44:
|6/25/2023
|6/25/2023
|
|
|PENDING
|COMPLETE
|
|
|Laveniya Satgunaseelan (LS)
|Laveniya Satgunaseelan (LS)
Line 50: Line 52:
|[[CNS5:Oligodendroglioma,_IDH-mutant_and_1p/19q-codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted]]
|[[CNS5:Oligodendroglioma,_IDH-mutant_and_1p/19q-codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted]]
|Disease
|Disease
|Riley Lochner (trainee), Shashi Shetty (mentor)
|Riley Lochner (trainee);
Shashi Shetty (mentor)
|6/7/2022
|6/7/2022
|
|
Line 61: Line 64:
|[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]]
|[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]]
|Disease
|Disease
|Meenakshi Mehrotra
|Jieying Wu
|
|11/18/2025
|
|01/15/2026
|PENDING
|PENDING
|
|
Line 75: Line 78:
|6/27/2023
|6/27/2023
|
|
|PENDING
|COMPLETE
|
|
|LS
|LS
Line 105: Line 108:
|[[CNS5:Diffuse_low-grade_glioma,_MAPK_pathway-altered_|Diffuse low-grade glioma, MAPK pathway-altered]]
|[[CNS5:Diffuse_low-grade_glioma,_MAPK_pathway-altered_|Diffuse low-grade glioma, MAPK pathway-altered]]
|Disease
|Disease
|Scott Smith
|5/3/2024
|
|
|PENDING - email reminder 9/4/2025
|
|
|
|LS
|
|
|
|
|
|
|
Line 116: Line 119:
|[[CNS5:Diffuse_midline_glioma,_H3_K27-altered|Diffuse midline glioma, H3 K27-altered]]
|[[CNS5:Diffuse_midline_glioma,_H3_K27-altered|Diffuse midline glioma, H3 K27-altered]]
|Disease
|Disease
|Laveniya Satgunaseelan (Linda Cooley - previous version)
|Laveniya Satgunaseelan
|
|
|
|12/06/2025
|PENDING
|PENDING
|
|
Line 135: Line 138:
|
|
|2021 template added
|2021 template added
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Diffuse_paediatric-type_high-grade_glioma,_H3-wildtype_and_IDH-wildtype|Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype]]
|[[CNS5:Diffuse_paediatric-type_high-grade_glioma,_H3-wildtype_and_IDH-wildtype|Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype]]
Line 160: Line 174:
|[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]]
|[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]]
|Disease
|Disease
|Jeremy Pulvers
|9/13/2022<br />
|
|
|PENDING
|<br />
|
|
|
|
|LS
|LS
Line 182: Line 196:
|[[CNS5:Pleomorphic_xanthoastrocytoma|Pleomorphic xanthoastrocytoma]]
|[[CNS5:Pleomorphic_xanthoastrocytoma|Pleomorphic xanthoastrocytoma]]
|Disease
|Disease
|Wahab Khan
|15/04/2025
|
|
|
|PENDING - email reminder 9/4/2025
|
|
|
|
|LS
|LS
Line 245: Line 259:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Desmoplastic_infantile_ganglioglioma_/_desmoplastic_infantile_astrocytoma|Desmoplastic infantile ganglioglioma / desmoplastic infantile astrocytoma]]
|[[CNS5:Desmoplastic_infantile_ganglioglioma_/_desmoplastic_infantile_astrocytoma|Desmoplastic infantile ganglioglioma / desmoplastic infantile astrocytoma]]
Line 314: Line 339:
|[[CNS5:Diffuse_leptomeningeal_glioneuronal_tumour|Diffuse leptomeningeal glioneuronal tumour]]
|[[CNS5:Diffuse_leptomeningeal_glioneuronal_tumour|Diffuse leptomeningeal glioneuronal tumour]]
|Disease
|Disease
|Laveniya Satgunaseelan
|9/11/2024
|
|
|
|COMPLETE
|
|8/7/2025
|
|LS
|
|LS
|
|Used for testing 9/2024 somatic template
|
|
|-
|-
|[[CNS5:Multinodular_and_vacuolating_neuronal_tumour|Multinodular and vacuolating neuronal tumour]]
|[[CNS5:Multinodular_and_vacuolating_neuronal_tumour|Multinodular and vacuolating neuronal tumour]]
Line 355: Line 380:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Extraventricular_neurocytoma|Extraventricular neurocytoma]]
|[[CNS5:Extraventricular_neurocytoma|Extraventricular neurocytoma]]
Line 466: Line 502:
|
|
|-
|-
|[[CNS5:Myxopapillary_ependymoma|Myxopapillary ependymoma]]
!'''Disease'''
|Disease
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[CNS5:Myxopapillary_ependymoma|Myxopapillary ependymoma]]
|Disease
|
|
|
|
Line 488: Line 535:
|
|
|-
|-
|CHAPTER 3 (CHOROID PLEXUS TUMOURS)
|
====CHAPTER 3 (CHOROID PLEXUS TUMOURS)====
|
|
----
----
Line 541: Line 589:
|
|
|-
|-
|CHAPTER 4 (EMBRYONAL TUMOURS)
|
====CHAPTER 4 (EMBRYONAL TUMOURS)====
|
|
----
----
Line 563: Line 612:
|[[CNS5:Medulloblastoma,_WNT-activated|Medulloblastoma, WNT-activated]]
|[[CNS5:Medulloblastoma,_WNT-activated|Medulloblastoma, WNT-activated]]
|Disease
|Disease
|Lisa Lansdon, PhD (LGG trainee just finished), Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City
|Lisa Lansdon, PhD (LGG trainee just finished);
Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City
|9/20/21
|9/20/21
|
|
Line 585: Line 635:
|[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]]
|[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]]
|Disease
|Disease
|Hannah Wollenzien
|1/11/2026
|
|
|Pending
|
|
|MS
|
|
|
|
|
|-
|
!'''Disease'''
|
!'''Page Type'''
|
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Medulloblastoma,_non-WNT/non-SHH|Medulloblastoma, non-WNT/non-SHH]]
|[[CNS5:Medulloblastoma,_non-WNT/non-SHH|Medulloblastoma, non-WNT/non-SHH]]
Line 682: Line 743:
|
|
|-
|-
|CHAPTER 5 (PINEAL TUMOURS)
|
====CHAPTER 5 (PINEAL TUMOURS)====
|
|
----
----
Line 712: Line 774:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Pineal_parenchymal_tumour_of_intermediate_differentiation|Pineal parenchymal tumour of intermediate differentiation]]
|[[CNS5:Pineal_parenchymal_tumour_of_intermediate_differentiation|Pineal parenchymal tumour of intermediate differentiation]]
Line 726: Line 799:
|[[CNS5:Pineoblastoma|Pineoblastoma]]
|[[CNS5:Pineoblastoma|Pineoblastoma]]
|Disease
|Disease
|Fang Fang (trainee)+Katie Schieffer (mentor)
|11/19/2025
|5/15/2026
|Pending
|
|
|LS
|
|
|
|
|
|-
|
|
|
|
|-
|[[CNS5:Papillary_tumour_of_the_pineal_region|Papillary tumour of the pineal region]]
|[[CNS5:Papillary_tumour_of_the_pineal_region|Papillary tumour of the pineal region]]
|Disease
|Disease
Line 757: Line 830:
|
|
|-
|-
|CHAPTER 6 (CRANIAL AND PARASPINAL NERVE TUMOURS)
|
====CHAPTER 6 (CRANIAL AND PARASPINAL NERVE TUMOURS)====
|
|
----
----
Line 831: Line 905:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]]
|[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]]
Line 854: Line 939:
|
|
|-
|-
|CHAPTER 7 (MENINGIOMA)
|
====CHAPTER 7 (MENINGIOMA)====
|
|
----
----
Line 885: Line 971:
|
|
|-
|-
|CHAPTER 8 (MESENCHYMAL, NON-MENINGOTHELIAL TUMOURS INVOLVING THE CNS)
|
====CHAPTER 8 (MESENCHYMAL, NON-MENINGOTHELIAL TUMOURS INVOLVING THE CNS)====
|
|
----
----
Line 959: Line 1,046:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]]
|[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]]
Line 1,026: Line 1,124:
|
|
|-
|-
|CHAPTER 9 (MELANOCYTIC TUMOURS)
|
====CHAPTER 9 (MELANOCYTIC TUMOURS)====
|
|
----
----
Line 1,068: Line 1,167:
|
|
|-
|-
|CHAPTER 10 (HAEMATOLYMPHOID TUMOURS INVOLVING THE CNS)
|
====CHAPTER 10 (HAEMATOLYMPHOID TUMOURS INVOLVING THE CNS)====
|
|
----
----
Line 1,099: Line 1,199:
|
|
|-
|-
|[[CNS5:Immunodeficiency-associated_CNS_lymphomas|Immunodeficiency-associated CNS lymphomas]]
!'''Disease'''
|Disease
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[CNS5:Immunodeficiency-associated_CNS_lymphomas|Immunodeficiency-associated CNS lymphomas]]
|Disease
|
|
|
|
Line 1,208: Line 1,319:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Langerhans_cell_histiocytosis|Langerhans cell histiocytosis]]
|[[CNS5:Langerhans_cell_histiocytosis|Langerhans cell histiocytosis]]
Line 1,231: Line 1,353:
|
|
|-
|-
|CHAPTER 11 (GERM CELL TUMOURS)
|
====CHAPTER 11 (GERM CELL TUMOURS)====
|
|
----
----
Line 1,262: Line 1,385:
|
|
|-
|-
|CHAPTER 12 (TUMOURS OF THE SELLAR REGION
|
====CHAPTER 12 (TUMOURS OF THE SELLAR REGION====
|
|
----
----
Line 1,337: Line 1,461:
|
|
|-
|-
|CHAPTER 13 (METASTASES TO THE CNS)
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|
====CHAPTER 13 (METASTASES TO THE CNS)====
|
|
----
----
Line 1,379: Line 1,515:
|
|
|-
|-
|CHAPTER 14 (GENETIC TUMOUR SYNDROMES INVOLVING THE CNS)
|
====CHAPTER 14 (GENETIC TUMOUR SYNDROMES INVOLVING THE CNS)====
|
|
----
----
Line 1,401: Line 1,538:
|[[CNS5:Neurofibromatosis_type_1|Neurofibromatosis type 1]]
|[[CNS5:Neurofibromatosis_type_1|Neurofibromatosis type 1]]
|Disease
|Disease
|Ngoni Faya (trainee) + Madina Sukhanova
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|NOT YET CREATED - See page "Neurofibromatosis Type 1 (NF1)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content.
|N/A
|-
|-
|[[CNS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]]
|[[CNS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|-
|-
|[[CNS5:Schwannomatosis|Schwannomatosis]]
|[[CNS5:Schwannomatosis|Schwannomatosis]]
Line 1,434: Line 1,571:
|[[CNS5:Von_Hippel-Lindau_syndrome|Von Hippel-Lindau syndrome]]
|[[CNS5:Von_Hippel-Lindau_syndrome|Von Hippel-Lindau syndrome]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|-
|-
|[[CNS5:Tuberous_sclerosis|Tuberous sclerosis]]
|[[CNS5:Tuberous_sclerosis|Tuberous sclerosis]]
Line 1,456: Line 1,593:
|[[CNS5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]]
|[[CNS5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Cowden_syndrome|Cowden syndrome]]
|[[CNS5:Cowden_syndrome|Cowden syndrome]]
|Disease
|Disease
|
|[[DIG5:Volunteer Assignments and Opportunities|See DIG5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|-
|-
|[[CNS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]]
|[[CNS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]]
|Disease
|Disease
|Jennie Thurston
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|7/2/2023
|N/A
|
|N/A
|PENDING
|N/A
|
|N/A
|LS
|N/A
|
|N/A
|NOT YET CREATED - See page "Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome (MLH1, PMS2, MSH2, MSH6)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content.
|N/A
|-
|-
|[[CNS5:Familial_adenomatous_polyposis_1|Familial adenomatous polyposis 1]]
|[[CNS5:Familial_adenomatous_polyposis_1|Familial adenomatous polyposis 1]]
|Disease
|Disease
|Jennifer Laffin
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|8/22/2023
|N/A
|
|N/A
|PENDING
|N/A
|
|N/A
|LS/MS
|N/A
|
|N/A
|NOT YET CREATED - See page "Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome (MLH1, PMS2, MSH2, MSH6)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content.
|N/A
|-
|-
|[[CNS5:Naevoid_basal_cell_carcinoma_syndrome|Naevoid basal cell carcinoma syndrome]]
|[[CNS5:Naevoid_basal_cell_carcinoma_syndrome|Naevoid basal cell carcinoma syndrome]]
Line 1,533: Line 1,681:
|[[CNS5:DICER1_syndrome|DICER1 syndrome]]
|[[CNS5:DICER1_syndrome|DICER1 syndrome]]
|Disease
|Disease
|Jennie Thurston
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|7/2/2023
|N/A
|
|N/A
|PENDING
|N/A
|
|N/A
|LS
|N/A
|
|N/A
|NOT YET CREATED - See page "''DICER1''-Related Tumour Predisposition Syndrome (''DICER1'')" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content.
|N/A
|-
|-
|[[CNS5:Familial_paraganglioma_syndromes|Familial paraganglioma syndromes]]
|[[CNS5:Familial_paraganglioma_syndromes|Familial paraganglioma syndromes]]
Line 1,574: Line 1,722:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]]
|[[CNS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]]
Line 1,588: Line 1,747:
|[[CNS5:Fanconi_anaemia|Fanconi anaemia]]
|[[CNS5:Fanconi_anaemia|Fanconi anaemia]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|-
|-
|[[CNS5:ELP1-medulloblastoma_syndrome|ELP1-medulloblastoma syndrome]]
|[[CNS5:ELP1-medulloblastoma_syndrome|ELP1-medulloblastoma syndrome]]
Retrieved from "https://test.ccga.io/index.php/CNS5:Volunteer_Assignments_and_Opportunities"